The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients
Exploring the Role of Gut-associated TH17 in Microbial Translocation in HIV and HCV/HIV Co-infected Patients
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT01335230, this observational or N/A phase trial focuses on HCV Coinfection and HIV and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 13 times since 2011, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Jun 2022 — Dec 2022 [monthly]
Completed
▶ Show 8 earlier versions
-
Dec 2021 — Jun 2022 [monthly]
Completed
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Nov 2020 — Jan 2021 [monthly]
Completed
-
Jun 2018 — Nov 2020 [monthly]
Completed
-
May 2018 — Jun 2018 [monthly]
Completed
-
Apr 2018 — May 2018 [monthly]
Completed
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Completed NA
-
Jan 2017 — Aug 2017 [monthly]
Completed NA
First recorded
Apr 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- University of Cincinnati
For direct contact, visit the study record on ClinicalTrials.gov .